Home > Oncology > ELCC 2019 > Immunotherapy in Stage 4 Lung Cancer > I-O monotherapy

I-O monotherapy

Presented By
Prof. Martin Reck, Airway Research Center North, Grosshansdorf, Germany
ELCC 2019
CheckMate 026, Keynote-024, Checkmate 227, MYSTIC, B-F1RST
Immuno-oncological (I-O) agents as monotherapy have shown superior efficacy compared to chemotherapy in both first- and second-line setting, with a consistent benefit in overall survival (OS) and a more favourable tolerability profile in high PD-L1 patients. There are three main reasons why we should discuss immuno-oncological (I-O) agents as monotherapy in non-small cell lung cancer (NSCLC). Firstly, I-O monotherapy has become a standard therapy in the second-line setting. “Some trials comparing an immune checkpoint inhibitor (ICI) as monotherapy with chemotherapy, showed a consistent benefit in OS favouring I-O monotherapy [1,2]”, Prof. Martin Reck (Airway Research Center North, Grosshansdorf, Germany) said at the beginning of his lecture. Furthermore, there is a clear correlation between a biomarker, i.e. PD-L1 expression, and the efficacy of I-O monotherapy. “This correlation is found across all agents we have investigated. In case of pembrolizumab (an...

Please login to read the full text of the article.

If you have no account yet, please register now.

Posted on